stockrowClene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024.
- Revenue
- +273.3%
- EPS
- +135.2%
- Free cash flow
- −16.6%
- Total debt
- −60.3%
Quarter to September 2026, against a year earlier
Follow CLNN
Alert me
Clene Inc. (CLNN) EV/Sales
As of 6 November 2026, Clene Inc. (CLNN) trades at a EV/Sales of 196×. Over the past ten years it has ranged from 0.0× (December 2020) to 2,186× (April 2021); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 331× | 181.72% |
| FY2024 | 118× | 872.17% |
| FY2023 | 12.1× | (90.13%) |
| FY2022 | 122× | (63.26%) |
| FY2022 | 333× | 8.90% |
| FY2021 | 306× | (16.37%) |
| FY2021 | 366× | (25.06%) |
| FY2020 | 488× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 209× | (51.52%) |
| Jun 2026 | 431× | (14.81%) |
| Mar 2026 | 506× | 52.82% |
| Dec 2025 | 331× | 1.40% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | −23.8× |
| XBIT XBiotech Inc. compare | −10.5× |
| BOLD Boundless Bio, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | 0.5× |
| GOSS Gossamer Bio, Inc. compare | 4.1× |
| RNXT RenovoRx, Inc. compare | 17.8× |
| CRDF Cardiff Oncology, Inc. compare | 39.8× |
| CLNN Clene Inc. | 196× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)